Harlan S Robins, Chief Scientific Officer, on June 15, 2026, sold 106,160 shares in Adaptive Biotechnologies (ADPT) for $1,847,942. Following the Form 4 filing with the SEC, Robins has control over a total of 1,405,898 common shares of the company, with 1,405,898 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1478320/000178085126000013/xslF345X05/form4.xml